Swiss National Bank Purchases 13,700 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Swiss National Bank lifted its position in Denali Therapeutics Inc. (NASDAQ:DNLIGet Rating) by 7.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 201,400 shares of the company’s stock after buying an additional 13,700 shares during the quarter. Swiss National Bank’s holdings in Denali Therapeutics were worth $5,927,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Exchange Traded Concepts LLC grew its stake in shares of Denali Therapeutics by 280.9% in the 2nd quarter. Exchange Traded Concepts LLC now owns 1,874 shares of the company’s stock valued at $55,000 after buying an additional 1,382 shares in the last quarter. Lazard Asset Management LLC bought a new stake in Denali Therapeutics during the second quarter worth approximately $157,000. Ergoteles LLC bought a new stake in Denali Therapeutics during the first quarter worth approximately $215,000. Bridgewater Associates LP bought a new stake in Denali Therapeutics during the first quarter worth approximately $221,000. Finally, GSA Capital Partners LLP boosted its position in Denali Therapeutics by 19.0% during the first quarter. GSA Capital Partners LLP now owns 6,940 shares of the company’s stock worth $223,000 after purchasing an additional 1,106 shares during the period. Institutional investors own 74.56% of the company’s stock.

Denali Therapeutics Stock Up 0.3 %

Shares of DNLI stock opened at $30.42 on Thursday. Denali Therapeutics Inc. has a 12 month low of $20.24 and a 12 month high of $48.46. The firm has a market cap of $4.13 billion, a PE ratio of -12.32 and a beta of 1.46. The stock has a 50 day moving average of $29.78 and a 200-day moving average of $29.68.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Morgan Stanley decreased their target price on Denali Therapeutics from $67.00 to $60.00 and set an “overweight” rating for the company in a research report on Tuesday, November 8th. BTIG Research raised Denali Therapeutics from a “neutral” rating to a “buy” rating and set a $38.00 target price for the company in a research report on Wednesday, November 2nd. Finally, Bank of America assumed coverage on Denali Therapeutics in a research report on Wednesday, November 2nd. They set a “buy” rating and a $40.00 target price for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $51.17.

Insider Transactions at Denali Therapeutics

In other news, Director Marc Tessier-Lavigne sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 28th. The stock was sold at an average price of $30.82, for a total transaction of $616,400.00. Following the completion of the transaction, the director now directly owns 1,910,356 shares in the company, valued at $58,877,171.92. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 12.70% of the company’s stock.

Denali Therapeutics Profile

(Get Rating)

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.

Featured Articles

Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLIGet Rating).

Institutional Ownership by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.